Veritas Farms, Inc (VFRM) Fair Value & Analysis
Healthcare · US · Market cap $16.4K
Veritas Farms, Inc
VFRM · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 7 days ago
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0003 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Veritas Farms, Inc (VFRM) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $884K. Revenue grew 135.5% year over year. Net debt stands at $4.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Veritas Farms, Inc. focuses on growing, producing, marketing, and distributing hemp oils and extracts containing phytocannabinoids. The company's products include capsules, gummies, tinctures, lotions, salves, cream, balm sticks, lip balms, and pet chews. It markets and sells its products under the Veritas Farms brand name, as well as through bulk, white label and private label custom formulations for distributors and retailers. The company was formerly known as SanSal Wellness Holdings, Inc. and changed its name to Veritas Farms, Inc. in February 2019. Veritas Farms, Inc. is based in Fort Lauderdale, Florida.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Veritas Farms, Inc reported revenue of $884K in FY2023 versus $7.3M in FY2019, a compound −41.0%/yr. Reported net income was −$5.8M in FY2023.
Is VFRM fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Veritas Farms, Inc (VFRM) undervalued?
What is the fair value of VFRM?
What is the quality score of VFRM?
What is the revenue of Veritas Farms, Inc (VFRM)?
What is the net profit margin of VFRM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.